Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29674510.
- Also identified by DOI 10.1158/1078-0432.CCR-18-0759 and PMC identifier 6082682.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Predictive tests, to refine the estrogen receptor assay, for the adjuvant treatment of breast cancer with tamoxifen and oral selective estrogen receptor degraders (SERD) are required. A splice variant of the corepressor NCOR2, BQ2313636.1 predicts tamoxifen resistance to adjuvant tamoxifen and AZ9496, the first oral SERD, completes phase I studies. <i>Clin Cancer Res; 24(15); 3480-2. ©2018 AACR</i><i>See related articles by Gong et al., p. 3681 and Hamilton et al., p. 3510</i>.
Medical subject headings
- Breast Neoplasms
- Tamoxifen